• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial
In conclusion, the effects of 1-month DAPT for the primary and major secondary endpoints were consistent in HBR and non-HBR patients without any significant interactions. The benefit of 1-month DAPT in reducing major bleeding was numerically greater in HBR patients.Clinical trial registration Short and optimal duration of dual antiplatelet therapy after everolimus-eluting cobalt –chromium stent-2 [STOPDAPT-2]; NCT02619760.
Source: Cardiovascular Intervention and Therapeutics - February 20, 2020 Category: Cardiology Source Type: research

Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis from Four Post-Approval Studies.
Conclusions: Compared to the non-HBR population, HBR patients experienced worse 4-year outcomes after PCI with CoCr everolimus-eluting stent. Both CTE and MB had a significant impact on subsequent risk of mortality irrespective of bleeding risk. PMID: 31992063 [PubMed - as supplied by publisher]
Source: Circulation - January 28, 2020 Category: Cardiology Authors: Sorrentino S, Claessen BE, Chandiramani R, Guedeney P, Vogel B, Baber U, Rau V, Wang J, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Liu Y, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann FJ, Hermiller J, Valgimigli M, Mehran R Tags: Circulation Source Type: research

Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study.
CONCLUSION: The POLBOS LM study will indicate the efficacy of BiOSS LIM C stent with contemporary PCI for distal left main bifurcation lesions in comparison with the XIENCE stent from the recent EXCEL trial, as a performance index. PMID: 31543500 [PubMed - as supplied by publisher]
Source: EuroIntervention - September 24, 2019 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

Effect on Clinical Restenosis of an Ultra‐Thin‐Strut Bare Metal Cobalt‐Chromium Stent Versus a Thin‐Strut Stainless Steel Stent
ConclusionsUltra‐thin strut Cro‐Co BMS is associated with a significant reduction of clinically driven TLR in all comers population with any type of coronary disease complexity.
Source: Journal of Interventional Cardiology - May 30, 2016 Category: Cardiology Authors: Simona Silenzi, Pierfrancesco Grossi, Luca Mariani, Chiara Fraccaro, Fabio Vagnarelli, Luciano Moretti Tags: Original Investigation Source Type: research

Effect on Clinical Restenosis of an Ultra ‐Thin‐Strut Bare Metal Cobalt‐Chromium Stent Versus a Thin‐Strut Stainless Steel Stent
ConclusionsUltra‐thin strut Cro‐Co BMS is associated with a significant reduction of clinically driven TLR in all comers population with any type of coronary disease complexity. (J Interven Cardiol 2016;29:300–310)
Source: Journal of Interventional Cardiology - May 30, 2016 Category: Cardiology Authors: Simona Silenzi, Pierfrancesco Grossi, Luca Mariani, Chiara Fraccaro, Fabio Vagnarelli, Luciano Moretti Tags: Original Investigation Source Type: research